Martina Zvěřová

Martina Zvěřová

Auto-generated profile, based on publicly available information

Martina Zvěřová

Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Clinical Biochemistry
Verified
Journal Article
Closed access
MZMartina Zvěřová
Martina Zvěřová

1 April 2014 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JPJan Pláteník
Jan Pláteník
ZFZdeněk Fišar
Zdeněk Fišar
RBRichard Buchal
Richard Buchal
RJRoman Jirák
Roman Jirák
EKEva Kitzlerová
Eva Kitzlerová
JRJiří Raboch
Jiří Raboch

1 November 2013 in Mitochondrion
Verified
Journal Article
Closed access
JHJana Hroudová
Jana Hroudová
ZFZdeněk Fišar
Zdeněk Fišar
EKEva Kitzlerová
Eva Kitzlerová
MZMartina Zvěřová
Martina Zvěřová
JRJiří Raboch
Jiří Raboch

2 June 2016 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
ZFZdeněk Fišar
Zdeněk Fišar
JHJana Hroudová
Jana Hroudová
JHJana Hroudová
Jana Hroudová
HHHana Hansíková
Hana Hansíková
JSJana Spá
Jana Spá
OVOvá
Ová
Mitochondrial dysfunctions significantly contribute to the pathogenesis of Alzheimer’s disease (AD). Here, we studied the relationship between AD and changes in the mitochondrial rates of respiration in blood platelets, respiratory chain complexes activity, and coenzyme Q10 plasma concentrations. In intact platelets obtained from AD patients, we observed a decrease in endogenous basal respiration rates, a decrease in the maximal capacity of the electron transport system (ETS), and higher respiratory rates after inhibiting complex I of the ETS. When normalized for citrate synthase activity, rotenone inhibited respiratory rates and complex I activity was significantly altered. In permeabilized platelets, mitochondrial respiration was completely rescued by the addition of complex I substrates. The changes in mitochondrial respiratory parameters were not associated with the progression of AD except for the capacity of the ETS in permeabilized platelets. In AD, complex I activity was increased, complex IV activity was decreased, and coenzyme Q10 plasma concentrations were decreased. Our data indicate that both insufficiency in substrates entering into the oxidative phosphorylation system and functional disturbances in the ETS complex are responsible for the decrease in respiration observed in intact platelets in AD patients. Analyses of complex IV activity, the respiratory rates of intact platelets, and the capacity of the ETS in permeabilized platelets may enable the characterization of mitochondrial dysfunctions in the initial stage of AD.

1 September 2019 in Mitochondrion
Verified
Journal Article
Closed access
ZFZdeněk Fišar
Zdeněk Fišar
HHHana Hansikova
Hana Hansikova
JKJana Křížová
Jana Křížová
RJRoman Jirák
Roman Jirák
EKEva Kitzlerová
Eva Kitzlerová
JRJiří Raboch
Jiří Raboch

1 July 2018 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
MZMartina Zvěřová
Martina Zvěřová
Alzheimer’s disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for AD is essential to improve diagnosis and accelerate the development of new therapies. Biochemical markers including neuroimaging could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment, and be used to detect the efficacies of disease-modifying therapies. Established biomarkers of AD from cerebrospinal fluid and neuroimaging are highly accurate, but barriers to clinical implementation exist. The focus on blood-based AD biomarkers has grown exponentially during the past few decades. An ideal diagnostic test for AD should be noninvasive and easily applicable. Clinical cost-effectiveness also needs to be established.